Expanding Access to Orphan Drugs
At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not...
View ArticleComplexities of Rare Diseases Take the Spotlight at BIO
Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease Track by addressing a packed session with a simple, powerful statement: “We’re all working to eliminate the...
View ArticleClik here to view.
The Washington Post Unfairly Attacks The Orphan Drug Act
The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled...
View ArticleClik here to view.
New Study Debunks Myths About Orphan Drug Act and Rare Disease Drug Costs
The Orphan Drug Act has been targeted recently by the insurance industry and its allies in the media, but in the face of withering criticism and unjustified allegations, a new study from IMS Health...
View ArticleClik here to view.
NORD and the Orphan Drug Act Celebrate 35 Years Driving Rare Disease...
The National Organization for Rare Disorders (NORD) has been instrumental in influencing public policy, regulatory frameworks, research, and economic discussions around rare diseases and orphan drugs....
View ArticleClik here to view.
BIO Illustrates the Success of the Orphan Drug Act
The numbers might surprise you. Approximately 7,000 rare diseases are known to exist, and approximately 30 new ones are identified each year. Also known as orphan diseases, they are defined as those...
View ArticleClik here to view.
Two New Infographics Illustrate the Success of the Orphan Drug Act
In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the success of the Orphan Drug Act and highlighting the importance of preserving incentives to help...
View ArticleClik here to view.
Senator Roberts is a Champion of Biotechnology Innovation
Last night, U.S. Senator Pat Roberts (R-Kan.) accepted BIO’s Lifetime Achievement Award, which recognized his leadership, service and commitment to advancing sound public policy that benefits America’s...
View ArticleClik here to view.
Why Concerns About a “Break Down” in Drug Pricing Are Misplaced
Just moments after it was announced the FDA had approved a new treatment for spinal muscular atrophy, Dr. Peter Bach was warning about a “break down” in the U.S. drug pricing system. It’s unfortunate...
View ArticleClik here to view.
Rare Disease Drug Development Increases but Challenges Remain
In a recent study published by Tufts University, researchers found that rare disease drug development is now one of the fastest growing areas in drug R&D, with nearly one-third of all products in...
View Article
